Shilpa Medicare soars over 11% to record high on positive phase 3 trial results for fatty liver drug NorUDCA
Shilpa Medicare shares surged over 11 percent to its record high after the company announced a successful outcome in Phase 3 studies for SMLNUD07, a drug known as NorUDCA. This medication is designed to treat patients with Nonalcoholic Fatty Liver Disease (NAFLD). Shilpa Medicare shares skyrocketed over 11 percent to reach a record high following …